Psoriasis Drugs Market: By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, and Topical Therapies), Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, and Other Mechanisms of Action), Route of Administration (Oral, Parenteral, and Topical), and Region

Purchase Option

$ 4400
$ 6600
$ 8900

Psoriasis Drugs Market size was valued at USD 12,000 million in 2022 and is poised to grow at a significant CAGR of 7% over 2023-2029. Psoriasis is an immune-mediated illness that results in a skin condition caused by systemic inflammation. The psoriasis drugs market players will benefit from an increase in psoriasis research and pipeline therapeutics and an increase in disease burden and demand for psoriasis treatments in emerging economies. For instance, in November 2020, Bristol Myers Squibb Presented Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis. Rising awareness programs about psoriasis disease and treatment alternatives, increased reimbursement support, and increased research and development with the introduction of biologics and biosimilars are all aspects that are influencing the psoriasis pharmaceuticals market and boosting sales growth. Furthermore, prominent market players engage in various business strategies such as product launches to grow their product portfolios and gain a competitive advantage. For example, in July 2020, Fujifilm Kyowa Kirin Biologics received regulatory approval in Japan to manufacture and market the first adalimumab biosimilar for treating psoriasis, Vulgaris arthritic psoriasis, and pustular psoriasis.

Psoriasis Drugs Market Key Developments:
  • In January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and impacts approximately 30 % of patients with psoriasis.
  • In December 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved Otezla (apremilast) to treat adult patients with plaque psoriasis candidates for phototherapy or systemic therapy.

Psoriasis Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Psoriasis Drugs Market Dynamics

The rising incidence of psoriasis worldwide has produced a significant demand for safe and effective treatments. This has driven manufacturing businesses to engage in research and development initiatives to develop new psoriasis treatment options. The market is driven by a strong product pipeline and growing regulatory approvals for products like Stelara (Janssen Pharmaceuticals) and Cimzia (UCB S.A.). However, the high medical costs associated with psoriasis therapy are one of the critical issues limiting demand for psoriasis medications. Increased spending on medication development for regulatory approvals and the patent filing procedure, which manufacturers are continually seeking to develop novel biological therapies, also limit the market growth. The lack of awareness regarding psoriasis and its related comorbidities is a prominent market restraint.

Psoriasis Drugs Market Segmentation

By Treatment
  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Topical Therapies
By Mechanism of Action
  • TNF Alpha Inhibitors
  • PDE4 Inhibitors
  • Interleukin Inhibitors
  • Other Mechanisms of Action
By Route of Administration
  • Oral
  • Parenteral
  • Topical

Frequently Asked Questions

The psoriasis drugs market is projected to expand at a CAGR of 7% during the forecast period.

AbbVie Inc., Eli Lilly, and Company, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd.    

Asia-Pacific is the fastest-growing region for psoriasis drugs market

Key Features of the Reports

  • The psoriasis drugs market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Psoriasis Drugs Market Introduction 
2.1.Global Psoriasis Drugs Market  - Taxonomy
2.2.Global Psoriasis Drugs Market  - Definitions
2.2.1. By Treatment
2.2.2. By Mechanism of Action
2.2.3. By Route of Administration
2.2.4. By Region
3.Global Psoriasis Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Psoriasis Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Psoriasis Drugs Market  By Treatment, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Biologic Drugs
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Small Molecule Systemic Drugs
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Topical Therapies
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Psoriasis Drugs Market  By Mechanism of Action, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. TNF Alpha Inhibitors
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. PDE4 Inhibitors
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Interleukin Inhibitors
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Other Mechanisms of Action
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Psoriasis Drugs Market  By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parenteral
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Topical
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Psoriasis Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Psoriasis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Biologic Drugs
9.1.2.Small Molecule Systemic Drugs
9.1.3.Topical Therapies
9.2.  Mechanism of Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.TNF Alpha Inhibitors
9.2.2.PDE4 Inhibitors
9.2.3.Interleukin Inhibitors
9.2.4.Other Mechanisms of Action
9.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Oral
9.3.2.Parenteral
9.3.3.Topical
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Psoriasis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Biologic Drugs
10.1.2.Small Molecule Systemic Drugs
10.1.3.Topical Therapies
10.2.  Mechanism of Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.TNF Alpha Inhibitors
10.2.2.PDE4 Inhibitors
10.2.3.Interleukin Inhibitors
10.2.4.Other Mechanisms of Action
10.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parenteral
10.3.3.Topical
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Psoriasis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Biologic Drugs
11.1.2.Small Molecule Systemic Drugs
11.1.3.Topical Therapies
11.2.  Mechanism of Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.TNF Alpha Inhibitors
11.2.2.PDE4 Inhibitors
11.2.3.Interleukin Inhibitors
11.2.4.Other Mechanisms of Action
11.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parenteral
11.3.3.Topical
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Psoriasis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Biologic Drugs
12.1.2.Small Molecule Systemic Drugs
12.1.3.Topical Therapies
12.2.  Mechanism of Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.TNF Alpha Inhibitors
12.2.2.PDE4 Inhibitors
12.2.3.Interleukin Inhibitors
12.2.4.Other Mechanisms of Action
12.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parenteral
12.3.3.Topical
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Psoriasis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Biologic Drugs
13.1.2.Small Molecule Systemic Drugs
13.1.3.Topical Therapies
13.2.  Mechanism of Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.TNF Alpha Inhibitors
13.2.2.PDE4 Inhibitors
13.2.3.Interleukin Inhibitors
13.2.4.Other Mechanisms of Action
13.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parenteral
13.3.3.Topical
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Janssen Biotech Inc
14.2.2.Novartis International Ltd.
14.2.3.Amgen Inc.
14.2.4.Pfizer Inc.
14.2.5.Takeda Pharmaceutical Company Ltd.
15. Research Methodology 
16. Appendix and Abbreviations 
  • Janssen Biotech Inc
  • Novartis International Ltd.
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Merck & Co Inc.
  • Abb Vie Inc.
  • Eli Lilly and Company
  • Boehringer Ingelheim GmbH
  • Sun Pharmaceutical Industries Ltd.

Adjacent Markets